# Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)

> **NCT01177384** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 380 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Sitagliptin phosphate
- **DRUG:** Comparator: Placebo
- **DRUG:** Acarbose
- **DRUG:** Glimepiride

## Key facts

- **NCT ID:** NCT01177384
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-25
- **Primary completion:** 2013-03-25
- **Final completion:** 2013-03-25
- **Target enrollment:** 380 (ACTUAL)
- **Last updated:** 2018-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01177384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01177384, "Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01177384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*